APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Influenza Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026

30 December 2025206 pages

Choose your research edition.

Industry ResearchMultivalent Influenza Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Multivalent Influenza Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multivalent Influenza Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multivalent Influenza Vaccines market include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multivalent Influenza Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multivalent Influenza Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multivalent Influenza Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multivalent Influenza Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Multivalent Influenza Vaccines Segment by Company

CSL

KM Biologics

Viatris

AstraZeneca

Bcht Biotechnology

Sinovac

Aleph Biomedical

GSK

ADIMMUNE Corporation

Hualan Bio

Jiangsu GDK

Sanofi

Shanghai Institute of Biological Products

Wuhan Institute of Biological Products

Changchun Institute of Biological

Zhongyianke Biotech

Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years

Above 3 Years

Multivalent Influenza Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Multivalent Influenza Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multivalent Influenza Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multivalent Influenza Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Multivalent Influenza Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Influenza Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multivalent Influenza Vaccines industry.

Chapter 3: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multivalent Influenza Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multivalent Influenza Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multivalent Influenza Vaccines Industry Trends Table 2. Multivalent Influenza Vaccines Industry Drivers Table 3. Multivalent Influenza Vaccines Industry Opportunities and Challenges Table 4. Multivalent Influenza Vaccines Industry Restraints Table 5. Global Multivalent Influenza Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multivalent Influenza Vaccines Revenue Share by Company (2021-2026) Table 7. Global Multivalent Influenza Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Multivalent Influenza Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Multivalent Influenza Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multivalent Influenza Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multivalent Influenza Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Multivalent Influenza Vaccines Company, Product Type & Application Table 13. Global Multivalent Influenza Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multivalent Influenza Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Quadrivalent Inactivated Influenza Vaccine (IIV4) Table 18. Significant Companies of Trivalent Inactivated Influenza Vaccine (IIV3) Table 19. Significant Companies of Trivalent Live Attenuated Vaccine (LAIV3) Table 20. Global Multivalent Influenza Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Multivalent Influenza Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Multivalent Influenza Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Multivalent Influenza Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global Multivalent Influenza Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global Multivalent Influenza Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Multivalent Influenza Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Multivalent Influenza Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Multivalent Influenza Vaccines Sales Value Share by Type (2021-2026) Table 29. Global Multivalent Influenza Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of 6 Months to 3 Years Table 31. Significant Companies of Above 3 Years Table 32. Global Multivalent Influenza Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Multivalent Influenza Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Multivalent Influenza Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Multivalent Influenza Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global Multivalent Influenza Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global Multivalent Influenza Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Multivalent Influenza Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Multivalent Influenza Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Multivalent Influenza Vaccines Sales Value Share by Application (2021-2026) Table 41. Global Multivalent Influenza Vaccines Sales Value Share by Application (2027-2032) Table 42. Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (K Units) Table 44. Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Multivalent Influenza Vaccines Sales by Region (2027-2032) & (K Units) Table 46. Global Multivalent Influenza Vaccines Sales Market Share by Region (2027-2032) Table 47. Global Multivalent Influenza Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Multivalent Influenza Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Multivalent Influenza Vaccines Sales Value Share by Region (2021-2026) Table 50. Global Multivalent Influenza Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Multivalent Influenza Vaccines Sales Value Share by Region (2027-2032) Table 52. Global Multivalent Influenza Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Multivalent Influenza Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Multivalent Influenza Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 57. Global Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 58. Global Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 59. Global Multivalent Influenza Vaccines Sales Market Share by Country (2027-2032) Table 60. Global Multivalent Influenza Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Multivalent Influenza Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global Multivalent Influenza Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Multivalent Influenza Vaccines Sales Value Market Share by Country (2027-2032) Table 64. CSL Company Information Table 65. CSL Business Overview Table 66. CSL Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. CSL Multivalent Influenza Vaccines Product Portfolio Table 68. CSL Recent Development Table 69. KM Biologics Company Information Table 70. KM Biologics Business Overview Table 71. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. KM Biologics Multivalent Influenza Vaccines Product Portfolio Table 73. KM Biologics Recent Development Table 74. Viatris Company Information Table 75. Viatris Business Overview Table 76. Viatris Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Viatris Multivalent Influenza Vaccines Product Portfolio Table 78. Viatris Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Multivalent Influenza Vaccines Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Bcht Biotechnology Company Information Table 85. Bcht Biotechnology Business Overview Table 86. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio Table 88. Bcht Biotechnology Recent Development Table 89. Sinovac Company Information Table 90. Sinovac Business Overview Table 91. Sinovac Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sinovac Multivalent Influenza Vaccines Product Portfolio Table 93. Sinovac Recent Development Table 94. Aleph Biomedical Company Information Table 95. Aleph Biomedical Business Overview Table 96. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio Table 98. Aleph Biomedical Recent Development Table 99. GSK Company Information Table 100. GSK Business Overview Table 101. GSK Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. GSK Multivalent Influenza Vaccines Product Portfolio Table 103. GSK Recent Development Table 104. ADIMMUNE Corporation Company Information Table 105. ADIMMUNE Corporation Business Overview Table 106. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio Table 108. ADIMMUNE Corporation Recent Development Table 109. Hualan Bio Company Information Table 110. Hualan Bio Business Overview Table 111. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Hualan Bio Multivalent Influenza Vaccines Product Portfolio Table 113. Hualan Bio Recent Development Table 114. Jiangsu GDK Company Information Table 115. Jiangsu GDK Business Overview Table 116. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio Table 118. Jiangsu GDK Recent Development Table 119. Sanofi Company Information Table 120. Sanofi Business Overview Table 121. Sanofi Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Sanofi Multivalent Influenza Vaccines Product Portfolio Table 123. Sanofi Recent Development Table 124. Shanghai Institute of Biological Products Company Information Table 125. Shanghai Institute of Biological Products Business Overview Table 126. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 128. Shanghai Institute of Biological Products Recent Development Table 129. Wuhan Institute of Biological Products Company Information Table 130. Wuhan Institute of Biological Products Business Overview Table 131. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 133. Wuhan Institute of Biological Products Recent Development Table 134. Changchun Institute of Biological Company Information Table 135. Changchun Institute of Biological Business Overview Table 136. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio Table 138. Changchun Institute of Biological Recent Development Table 139. Zhongyianke Biotech Company Information Table 140. Zhongyianke Biotech Business Overview Table 141. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio Table 143. Zhongyianke Biotech Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Multivalent Influenza Vaccines Distributors List Table 147. Multivalent Influenza Vaccines Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Multivalent Influenza Vaccines Product Image Figure 2. Global Multivalent Influenza Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multivalent Influenza Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Multivalent Influenza Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multivalent Influenza Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Quadrivalent Inactivated Influenza Vaccine (IIV4) Image Figure 10. Trivalent Inactivated Influenza Vaccine (IIV3) Image Figure 11. Trivalent Live Attenuated Vaccine (LAIV3) Image Figure 12. Global Multivalent Influenza Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Multivalent Influenza Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Multivalent Influenza Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global Multivalent Influenza Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Multivalent Influenza Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Multivalent Influenza Vaccines Sales Value Share by Type (2021-2032) Figure 18. 6 Months to 3 Years Image Figure 19. Above 3 Years Image Figure 20. Global Multivalent Influenza Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Multivalent Influenza Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Multivalent Influenza Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global Multivalent Influenza Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Multivalent Influenza Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Multivalent Influenza Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Multivalent Influenza Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Multivalent Influenza Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Multivalent Influenza Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America Multivalent Influenza Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Multivalent Influenza Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Multivalent Influenza Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America Multivalent Influenza Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Multivalent Influenza Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Multivalent Influenza Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Multivalent Influenza Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Multivalent Influenza Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Quadrivalent Inactivated Influenza Vaccine (IIV4)
  • Trivalent Inactivated Influenza Vaccine (IIV3)
  • Trivalent Live Attenuated Vaccine (LAIV3)
Applications
  • 6 Months to 3 Years
  • Above 3 Years
Companies covered
  • CSL
  • KM Biologics
  • Viatris
  • AstraZeneca
  • Bcht Biotechnology
  • Sinovac
  • Aleph Biomedical
  • GSK
  • ADIMMUNE Corporation
  • Hualan Bio
  • Jiangsu GDK
  • Sanofi
  • Shanghai Institute of Biological Products
  • Wuhan Institute of Biological Products
  • Changchun Institute of Biological
  • Zhongyianke Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multivalent Influenza Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Multivalent Influenza Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Multivalent Influenza Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multivalent Influenza Vaccines Market Dynamics
  1. 2.1 Multivalent Influenza Vaccines Industry Trends
  2. 2.2 Multivalent Influenza Vaccines Industry Drivers
  3. 2.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Influenza Vaccines Industry Restraints
3 Multivalent Influenza Vaccines Market by Company
  1. 3.1 Global Multivalent Influenza Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Multivalent Influenza Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Multivalent Influenza Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Multivalent Influenza Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Multivalent Influenza Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Multivalent Influenza Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Multivalent Influenza Vaccines Company Product Type and Application
  8. 3.8 Global Multivalent Influenza Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multivalent Influenza Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multivalent Influenza Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multivalent Influenza Vaccines Market by Type
  1. 4.1 Multivalent Influenza Vaccines Type Introduction
  2. 4.1.1 Quadrivalent Inactivated Influenza Vaccine (IIV4)
  3. 4.1.2 Trivalent Inactivated Influenza Vaccine (IIV3)
  4. 4.1.3 Trivalent Live Attenuated Vaccine (LAIV3)
  5. 4.2 Global Multivalent Influenza Vaccines Sales Volume by Type
  6. 4.2.1 Global Multivalent Influenza Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multivalent Influenza Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Multivalent Influenza Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Multivalent Influenza Vaccines Sales Value by Type
  10. 4.3.1 Global Multivalent Influenza Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Multivalent Influenza Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global Multivalent Influenza Vaccines Sales Value Share by Type (2021-2032)
5 Multivalent Influenza Vaccines Market by Application
  1. 5.1 Multivalent Influenza Vaccines Application Introduction
  2. 5.1.1 6 Months to 3 Years
  3. 5.1.2 Above 3 Years
  4. 5.2 Global Multivalent Influenza Vaccines Sales Volume by Application
  5. 5.2.1 Global Multivalent Influenza Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multivalent Influenza Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Multivalent Influenza Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Multivalent Influenza Vaccines Sales Value by Application
  9. 5.3.1 Global Multivalent Influenza Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multivalent Influenza Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Multivalent Influenza Vaccines Sales Value Share by Application (2021-2032)
6 Multivalent Influenza Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multivalent Influenza Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Multivalent Influenza Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Multivalent Influenza Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Multivalent Influenza Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multivalent Influenza Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multivalent Influenza Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multivalent Influenza Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Multivalent Influenza Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multivalent Influenza Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Multivalent Influenza Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multivalent Influenza Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Multivalent Influenza Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multivalent Influenza Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multivalent Influenza Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multivalent Influenza Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Multivalent Influenza Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multivalent Influenza Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multivalent Influenza Vaccines Sales Value Share by Country, 2025 VS 2032
7 Multivalent Influenza Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multivalent Influenza Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multivalent Influenza Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Multivalent Influenza Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Multivalent Influenza Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Multivalent Influenza Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multivalent Influenza Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multivalent Influenza Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multivalent Influenza Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multivalent Influenza Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multivalent Influenza Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 KM Biologics
  8. 8.2.1 KM Biologics Company Information
  9. 8.2.2 KM Biologics Business Overview
  10. 8.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
  12. 8.2.5 KM Biologics Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Bcht Biotechnology
  26. 8.5.1 Bcht Biotechnology Company Information
  27. 8.5.2 Bcht Biotechnology Business Overview
  28. 8.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
  30. 8.5.5 Bcht Biotechnology Recent Developments
  31. 8.6 Sinovac
  32. 8.6.1 Sinovac Company Information
  33. 8.6.2 Sinovac Business Overview
  34. 8.6.3 Sinovac Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
  36. 8.6.5 Sinovac Recent Developments
  37. 8.7 Aleph Biomedical
  38. 8.7.1 Aleph Biomedical Company Information
  39. 8.7.2 Aleph Biomedical Business Overview
  40. 8.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
  42. 8.7.5 Aleph Biomedical Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 ADIMMUNE Corporation
  50. 8.9.1 ADIMMUNE Corporation Company Information
  51. 8.9.2 ADIMMUNE Corporation Business Overview
  52. 8.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
  54. 8.9.5 ADIMMUNE Corporation Recent Developments
  55. 8.10 Hualan Bio
  56. 8.10.1 Hualan Bio Company Information
  57. 8.10.2 Hualan Bio Business Overview
  58. 8.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
  60. 8.10.5 Hualan Bio Recent Developments
  61. 8.11 Jiangsu GDK
  62. 8.11.1 Jiangsu GDK Company Information
  63. 8.11.2 Jiangsu GDK Business Overview
  64. 8.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
  66. 8.11.5 Jiangsu GDK Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Shanghai Institute of Biological Products
  74. 8.13.1 Shanghai Institute of Biological Products Company Information
  75. 8.13.2 Shanghai Institute of Biological Products Business Overview
  76. 8.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  78. 8.13.5 Shanghai Institute of Biological Products Recent Developments
  79. 8.14 Wuhan Institute of Biological Products
  80. 8.14.1 Wuhan Institute of Biological Products Company Information
  81. 8.14.2 Wuhan Institute of Biological Products Business Overview
  82. 8.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  84. 8.14.5 Wuhan Institute of Biological Products Recent Developments
  85. 8.15 Changchun Institute of Biological
  86. 8.15.1 Changchun Institute of Biological Company Information
  87. 8.15.2 Changchun Institute of Biological Business Overview
  88. 8.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
  90. 8.15.5 Changchun Institute of Biological Recent Developments
  91. 8.16 Zhongyianke Biotech
  92. 8.16.1 Zhongyianke Biotech Company Information
  93. 8.16.2 Zhongyianke Biotech Business Overview
  94. 8.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
  96. 8.16.5 Zhongyianke Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multivalent Influenza Vaccines Value Chain Analysis
  2. 9.1.1 Multivalent Influenza Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multivalent Influenza Vaccines Sales Mode & Process
  6. 9.2 Multivalent Influenza Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multivalent Influenza Vaccines Distributors
  9. 9.2.3 Multivalent Influenza Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst